AZENTA INC (AZTA) Fundamental Analysis & Valuation

NASDAQ:AZTA • US1143401024

Current stock price

24.32 USD
-0.63 (-2.53%)
At close:
24.32 USD
0 (0%)
After Hours:

This AZTA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. AZTA Profitability Analysis

1.1 Basic Checks

  • AZTA had positive earnings in the past year.
  • In the past year AZTA had a positive cash flow from operations.
  • In multiple years AZTA reported negative net income over the last 5 years.
  • Of the past 5 years AZTA 4 years had a positive operating cash flow.
AZTA Yearly Net Income VS EBIT VS OCF VS FCFAZTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B 1.5B 2B

1.2 Ratios

  • AZTA's Return On Assets of -2.79% is in line compared to the rest of the industry. AZTA outperforms 57.89% of its industry peers.
  • AZTA has a Return On Equity of -3.37%. This is in the better half of the industry: AZTA outperforms 61.40% of its industry peers.
Industry RankSector Rank
ROA -2.79%
ROE -3.37%
ROIC N/A
ROA(3y)-3.69%
ROA(5y)10.48%
ROE(3y)-4.38%
ROE(5y)11.73%
ROIC(3y)N/A
ROIC(5y)N/A
AZTA Yearly ROA, ROE, ROICAZTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

1.3 Margins

  • The Gross Margin of AZTA (44.59%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of AZTA has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for AZTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y0.54%
AZTA Yearly Profit, Operating, Gross MarginsAZTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 200 300

8

2. AZTA Health Analysis

2.1 Basic Checks

  • AZTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, AZTA has more shares outstanding
  • The number of shares outstanding for AZTA has been reduced compared to 5 years ago.
  • Compared to 1 year ago, AZTA has an improved debt to assets ratio.
AZTA Yearly Shares OutstandingAZTA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
AZTA Yearly Total Debt VS Total AssetsAZTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 3.42 indicates that AZTA is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.42, AZTA is in the better half of the industry, outperforming 70.18% of the companies in the same industry.
  • There is no outstanding debt for AZTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.42
ROIC/WACCN/A
WACC10.94%
AZTA Yearly LT Debt VS Equity VS FCFAZTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

2.3 Liquidity

  • AZTA has a Current Ratio of 2.92. This indicates that AZTA is financially healthy and has no problem in meeting its short term obligations.
  • AZTA has a Current ratio (2.92) which is comparable to the rest of the industry.
  • AZTA has a Quick Ratio of 2.61. This indicates that AZTA is financially healthy and has no problem in meeting its short term obligations.
  • AZTA's Quick ratio of 2.61 is in line compared to the rest of the industry. AZTA outperforms 57.89% of its industry peers.
Industry RankSector Rank
Current Ratio 2.92
Quick Ratio 2.61
AZTA Yearly Current Assets VS Current LiabilitesAZTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

5

3. AZTA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 14.89% over the past year.
  • AZTA shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -16.04% yearly.
  • AZTA shows a decrease in Revenue. In the last year, the revenue decreased by -8.40%.
  • Measured over the past years, AZTA shows a quite strong growth in Revenue. The Revenue has been growing by 8.86% on average per year.
EPS 1Y (TTM)14.89%
EPS 3Y0.64%
EPS 5Y-16.04%
EPS Q2Q%12.5%
Revenue 1Y (TTM)-8.4%
Revenue growth 3Y2.25%
Revenue growth 5Y8.86%
Sales Q2Q%0.77%

3.2 Future

  • Based on estimates for the next years, AZTA will show a very strong growth in Earnings Per Share. The EPS will grow by 27.49% on average per year.
  • The Revenue is expected to grow by 5.37% on average over the next years.
EPS Next Y50.47%
EPS Next 2Y43.51%
EPS Next 3Y35.52%
EPS Next 5Y27.49%
Revenue Next Year5.15%
Revenue Next 2Y5.46%
Revenue Next 3Y5.78%
Revenue Next 5Y5.37%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AZTA Yearly Revenue VS EstimatesAZTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
AZTA Yearly EPS VS EstimatesAZTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2 2.5

5

4. AZTA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 45.04 indicates a quite expensive valuation of AZTA.
  • Compared to the rest of the industry, the Price/Earnings ratio of AZTA indicates a somewhat cheap valuation: AZTA is cheaper than 61.40% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.53. AZTA is valued rather expensively when compared to this.
  • With a Price/Forward Earnings ratio of 22.28, AZTA is valued on the expensive side.
  • 77.19% of the companies in the same industry are more expensive than AZTA, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 37.95, AZTA is valued a bit cheaper.
Industry RankSector Rank
PE 45.04
Fwd PE 22.28
AZTA Price Earnings VS Forward Price EarningsAZTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • AZTA's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. AZTA is cheaper than 78.95% of the companies in the same industry.
  • 63.16% of the companies in the same industry are more expensive than AZTA, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 36.22
EV/EBITDA 16.7
AZTA Per share dataAZTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • AZTA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • AZTA's earnings are expected to grow with 35.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.89
PEG (5Y)N/A
EPS Next 2Y43.51%
EPS Next 3Y35.52%

0

5. AZTA Dividend Analysis

5.1 Amount

  • No dividends for AZTA!.
Industry RankSector Rank
Dividend Yield 0%

AZTA Fundamentals: All Metrics, Ratios and Statistics

AZENTA INC

NASDAQ:AZTA (4/16/2026, 8:14:46 PM)

After market: 24.32 0 (0%)

24.32

-0.63 (-2.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-04
Earnings (Next)05-05
Inst Owners116.07%
Inst Owner Change0.01%
Ins Owners0.69%
Ins Owner Change12.39%
Market Cap1.12B
Revenue(TTM)594.95M
Net Income(TTM)-57.85M
Analysts77.14
Price Target37.74 (55.18%)
Short Float %11.64%
Short Ratio5.43
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.65%
Min EPS beat(2)-35.95%
Max EPS beat(2)8.65%
EPS beat(4)2
Avg EPS beat(4)-5.26%
Min EPS beat(4)-35.95%
Max EPS beat(4)36.22%
EPS beat(8)6
Avg EPS beat(8)46.66%
EPS beat(12)9
Avg EPS beat(12)140.12%
EPS beat(16)13
Avg EPS beat(16)118.13%
Revenue beat(2)0
Avg Revenue beat(2)-0.51%
Min Revenue beat(2)-0.98%
Max Revenue beat(2)-0.05%
Revenue beat(4)0
Avg Revenue beat(4)-1.7%
Min Revenue beat(4)-5.56%
Max Revenue beat(4)-0.05%
Revenue beat(8)1
Avg Revenue beat(8)-1.26%
Revenue beat(12)4
Avg Revenue beat(12)-0.9%
Revenue beat(16)6
Avg Revenue beat(16)-1.08%
PT rev (1m)-1.89%
PT rev (3m)-4.78%
EPS NQ rev (1m)-0.49%
EPS NQ rev (3m)-24.05%
EPS NY rev (1m)-0.71%
EPS NY rev (3m)-0.16%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)0.11%
Revenue NY rev (1m)0.47%
Revenue NY rev (3m)0.59%
Valuation
Industry RankSector Rank
PE 45.04
Fwd PE 22.28
P/S 1.88
P/FCF 36.22
P/OCF 17.95
P/B 0.65
P/tB 1.22
EV/EBITDA 16.7
EPS(TTM)0.54
EY2.22%
EPS(NY)1.09
Fwd EY4.49%
FCF(TTM)0.67
FCFY2.76%
OCF(TTM)1.35
OCFY5.57%
SpS12.92
BVpS37.23
TBVpS19.88
PEG (NY)0.89
PEG (5Y)N/A
Graham Number21.2685 (-12.55%)
Profitability
Industry RankSector Rank
ROA -2.79%
ROE -3.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.59%
FCFM 5.2%
ROA(3y)-3.69%
ROA(5y)10.48%
ROE(3y)-4.38%
ROE(5y)11.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y0.54%
F-Score5
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 55.45%
Cap/Sales 5.29%
Interest Coverage N/A
Cash Conversion 156.34%
Profit Quality N/A
Current Ratio 2.92
Quick Ratio 2.61
Altman-Z 3.42
F-Score5
WACC10.94%
ROIC/WACCN/A
Cap/Depr(3y)47.53%
Cap/Depr(5y)73.52%
Cap/Sales(3y)6.46%
Cap/Sales(5y)8.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.89%
EPS 3Y0.64%
EPS 5Y-16.04%
EPS Q2Q%12.5%
EPS Next Y50.47%
EPS Next 2Y43.51%
EPS Next 3Y35.52%
EPS Next 5Y27.49%
Revenue 1Y (TTM)-8.4%
Revenue growth 3Y2.25%
Revenue growth 5Y8.86%
Sales Q2Q%0.77%
Revenue Next Year5.15%
Revenue Next 2Y5.46%
Revenue Next 3Y5.78%
Revenue Next 5Y5.37%
EBIT growth 1Y71.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year493.88%
EBIT Next 3Y107.95%
EBIT Next 5YN/A
FCF growth 1Y-4.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.01%
OCF growth 3YN/A
OCF growth 5Y13.75%

AZENTA INC / AZTA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AZENTA INC?

ChartMill assigns a fundamental rating of 5 / 10 to AZTA.


What is the valuation status for AZTA stock?

ChartMill assigns a valuation rating of 5 / 10 to AZENTA INC (AZTA). This can be considered as Fairly Valued.


Can you provide the profitability details for AZENTA INC?

AZENTA INC (AZTA) has a profitability rating of 3 / 10.


How financially healthy is AZENTA INC?

The financial health rating of AZENTA INC (AZTA) is 8 / 10.


What is the expected EPS growth for AZENTA INC (AZTA) stock?

The Earnings per Share (EPS) of AZENTA INC (AZTA) is expected to grow by 50.47% in the next year.